We are studying how personalized dosing of ibrutinib can improve treatment for patients with previously untreated chronic lymphocytic leukemia. The goal is to see if adjusting the dose based on side effects leads to better outcomes.
Health conditions and diseases that the clinical trial is designed to study and treat.
Chronic Lymphocytic Leukemia (CLL) is a type of cancer that affects the blood and bone marrow, characterized by the overproduction of abnormal lymphocytes. It often progresses slowly and may not cause symptoms initially.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
